Evaxion Biotech AS (EVAX) Stock Forecast & Price Target
Evaxion Biotech AS · NASDAQ
$3.36-0.04 (-1.18%)
15-min delayed · Aug 25, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Evaxion Biotech AS, 4 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $16.00 to $16.00, so the covering firms are broadly aligned. The average target of $16.00 sits 376% above the current $3.36. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.01 next quarter toward $-0.01 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Strong Buy
Strong Buy00%
Buy4100%
Hold00%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Evaxion Biotech AS.
As of Aug, 4 of 4 firms rate EVAX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
EVAX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.01
Range $-0.01 – $-0.01 · 1 analysts · +0% YoY
Next period, 1 analysts expect Evaxion Biotech AS to earn $-0.01 a share (range $-0.01 – $-0.01), versus $-0.01 a year earlier. Full-year consensus is $-0.04, growing to $-0.01 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $4.7M next year.
Top analysts covering Evaxion Biotech AS
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on EVAX.
#1
TF
Thomas Flaten
Lake Street · Rank #229
Buy
$9.00+167.9% to target
Overall win rate
40%
+ Follow
#2
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #243
Buy
$16.00+376.2% to target
Overall win rate
38%
+ Follow
#3
DC
Debanjana Chatterjee
JonesTrading
Buy
$10.00+197.6% to target
Coverage
—
+ Follow
#4
Michael Okunewitch
Maxim Group
Buy
$10.00+197.6% to target
Coverage
—
+ Follow
EVAX stock forecast FAQ
What is EVAX's average 12-month price target?+
The 1 analysts with a live target average $16.00 for Evaxion Biotech AS over the next 12 months, ranging from a $16.00 high to a $16.00 low.
Is EVAX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 4 analyst ratings, 4 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover EVAX?+
4 analysts have an active rating on Evaxion Biotech AS, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering EVAX?+
Among analysts who currently cover EVAX, Thomas Flaten of Lake Street has the strongest overall Quantellect track record (Rank #229). Their current call is Buy with a $9.00 target.
What is Evaxion Biotech AS's projected EPS for next quarter?+
The consensus estimate is $-0.01 per share (range $-0.01 – $-0.01) across 1 analysts. Full-year EPS is projected at $-0.04, rising to $-0.01 the following year.
How much revenue is Evaxion Biotech AS expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $4.7M next year.
Have analysts been upgrading or downgrading EVAX lately?+
As of Aug, 4 of 4 firms rate EVAX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their EVAX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
